ATA Inc. Stock News

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that Beckley Psytech has dosed the first patient in the second part of its Phase 2a study of its novel intranasal 5-MeO-MDT drug candidate BPL-003 i

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the results of investee Beckley Beckley Psytech's Phase 1 study of its novel, novel, synthetic, intranasal benzoate salt formulation of 5-MeO-D

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus on psychedelic-based treatments for depression.   CEO and

Does atai Life Sciences N.V. (ATAI) have what it takes to be a top stock pick for momentum investors?

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it has enough cash, marketable securities, and a committed loan facility to support its operations into 2026 as it continues to advance psychedelic-based

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has hailed positive results from its investee Beckley Psytech's Phase 2a study of its novel DMT formulation BPL-003 in patients with treatment-resistant depre

Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there's still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine

Psychedelics stocks could be buoyed by a few positive events soon. The government is now funding the study of certain psychedelics.

Psychedelic drug development firm atai Life Sciences (NASDAQ:ATAI) is investing $50 million in UK-based Beckley Psytech as part of a collaboration that gives the company exposure to a Phase 2 psychede

atai Life Sciences (NASDAQ:ATAI) shares moved more than 13% higher Tuesday after the company reported positive findings from its early-stage study of EMP-01, Atai's R-isomer of MDMA. The company said

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and

Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are giv

atai Life Sciences N.V. (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The success of a Phase 3 trial of MDMA for post-traumatic stress disorder (PTSD) which has put the therapy on track for U.S. Food and Drug Administration (FDA) approval in 2024 has been celebrated by

NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health d